Pharma Digest

Pharma Digest

By Jan MajtaScienceLife Sciences
Download on the App Store

Pharma Digest episodes

  • Episode#19 Mar 10th 2026: Vertex races to FDA
    • Vertex races to FDA after phase 3 kidney disease data impress analysts
    • Servier Boosts Presence in Rare Cancers With $2.5B Acquisition of Day One Biopharma
    • FDA reconsidering Capricor’s snubbed DMD cell therapy after 'lifting' rejection
    15 min
  • Episode#17 Mar 09th 2026: FDA OK for Tecvayli
    • FDA issues speedy approval to J&J’s Tecvayli-Darzalex combo
    • Xenon phase 3 epilepsy readout 'blows away' expectations, stock soars
    • BMS builds momentum for CELMoD drug after improving myeloma PFS in phase 3
    15 min
  • Episode#16 Mar 06th 2026: Future of Health Tech
    • Future of Health Tech: From Structured Data to Scalable AI
    • Capturing the Vibe at ViVE 2026, Healthcare Executives Share Insights on Medication Adherence and Implementing AI
    • Privacy Expectations in Consumer AI Tools: How Patient Use of ChatGPT Health and Claude Differs From HIPAA-Regulated Care
    21 min
  • Episode#15 Mar 06th 2026: Merck KGaA drops pipeline assets
    • Merck KGaA drops pipeline assets from SpringWorks buyout, Hengrui licensing deal
    • FDA to end 9-month advisory committee drought with April review of AstraZeneca’s oral SERD, Truqap
    • Roche pumps $480M into South Korea biopharma industry to establish global trial 'ecosystem'
    22 min
  • Episode#14 Mar 05th 2026: Episode: AI antibiotics
    • Opinion: AI could revolutionize antibiotics — but the market is standing in the way
    • Third Way Health Secures $15M to Streamline Front-Office Operations for Medical Practices
    • In­vestors are pump­ing mon­ey in­to AI tools for health in­sur­ers

    23 min
  • Episode#13 Mar 05th 2026: UCB enters TCE space
    • UCB enters TCE space with $1.1B deal for Chinese biotech's autoimmune candidate
    • New cancer cases prompt Kyowa to discontinue late‑stage autoimmune disease program
    • FDA details rationale for rejecting rare disease gene therapy from Regenxbio
    21 min
  • Episode#10 Mar 03th 2026: Senhwa-CellType Collaboration, Generate's IPO
    • Senhwa's CX-4945 targets CK2 kinase with dual tumor and immune modulatory mechanisms; CellType's AI platform aims to expand indications and improve clinical success via multi-omics analysis and translational validation.
    • Generate's $400M IPO signals strong investor confidence, driven by AI-designed pipelines including GB-0895, an AI-optimized TSLP inhibitor with potential to disrupt asthma treatment.
    • hysiology remains foundational for translating AI and sensor data into clinically relevant therapies, aiding in anticipating off-target effects and enhancing regulatory acceptance.
    13 min

About Pharma Digest

From the publisher's feed

A fast paced, AI-generated podcast on pharma and biotech news.